Newcastle University

Binance Launchpool to launch BIO Protocol (BIO) on Jan 3, 2025, with 3.32B total tokens, 39.05% circulating. BIO allocates 56% to ecosystem, 25.4% to contributors, 18.6% to supporters. DeSci market heats up with tokens like VITA, GROW, RSC rising. BIO ecosystem includes DeSci DAOs, NFTs, meme coins, and IPTs, offering speculative opportunities. BIO Protocol's 2025 roadmap includes TGE on Ethereum, launches on Solana/Base, new BioDAOs, liquidity pools, and BIO Launchpad.

Tharimmune plans to initiate a Phase 2 study of TH104 for moderate-to-severe pruritus in PBC patients in 2025, following positive Phase 1 results and regulatory feedback. The company achieved milestones in manufacturing, clinical trials, and regulatory progress in 2024, and expanded its Board of Directors with the appointment of Sanam Parikh.

Northstar Ventures adds Dr. Will Cousins as investment manager, enhancing its life sciences portfolio and seeking new investment opportunities. Cousins, with a PhD in translational and clinical research, is passionate about venture capital and early-stage investments, aiming to translate biotechnology innovations into commercially viable solutions.

Geroscience aims to extend healthspan by studying aging mechanisms and developing interventions. Challenges include multimorbidity and polypharmacy in older patients, requiring novel trial designs. Miles Witham discusses the need for interventions with minimal side effects, potential of drug repurposing, and strategies for inclusive trial recruitment. AI and machine learning could aid in patient matching and integrating high-dimensional biomarker data.

CervoMed Inc. presented data at CTAD 2024 showing neflamapimod reduces plasma GFAP levels in DLB patients, correlating with clinical improvements. The RewinD-LB Phase 2b trial, set to report in December, aims to confirm these effects in a DLB population optimized for treatment response.

Neflamapimod reduced plasma GFAP levels and improved clinical outcomes in DLB patients, with RewinD-LB Phase 2b trial enrolling DLB patients without tau pathology for optimized treatment effect evaluation.

Astex Pharmaceuticals to present five key data on ASTX528 and ASTX295 at the 36th EORTC-NCI-AACR Symposium in Barcelona, focusing on novel small-molecule CBP/p300 HAT domain inhibitor and Phase II-ready MDM2 antagonist.